Adenoviral vectors are a safe and potently immunogenic vaccine delivery platform. Non-
replicating Ad vectors possess several attributes which make them attractive vaccines for …

Adenovirus was originally used as a vector for gene therapy. In recent years, with the
development of the next-generation vectors with increased safety and high immunogenicity …

Influenza viruses are responsible for millions of cases globally and significantly threaten
public health. Since pandemic and zoonotic influenza viruses have emerged in the last 20 …

Vaccine development has been hampered by the long lead times and the high cost required
to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that …

The use of vaccination against the influenza virus remains the most effective method of
mitigating the significant morbidity and mortality caused by this virus. Antibodies elicited by …

It is evident that the emergence of infectious diseases, which have the potential for spillover
from animal reservoirs, pose an ongoing threat to global health. Zoonotic transmission …

A series of recombinant human type 5 adenoviruses that express the full-length or
membrane-truncated spike protein (S) of SARS-CoV-2 (AdCoV2-S or AdCoV2-SdTM …

Adenoviral (Ad) vectors represent promising vaccine platforms for infectious disease. To
overcome pre-existing immunity to commonly used human adenovirus serotype 5 (Ad5) …

Since the development of the first vaccine against smallpox over two centuries ago,
vaccination strategies have been at the forefront of significantly impacting the incidences of …

New vaccine technologies are being investigated for their ability to elicit broadly cross-
protective immunity against a range of influenza viruses. We compared the efficacies of two …